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NomeNclature
IR  Ionising radiation
US FDA United States food and drug administration
cAMP Cyclic adenosine monophosphate
NOS Nitric oxide synthase
ATP Adenosine triphosphate
GO  Gene Ontology
STITCH Search tool for interactions of chemicals
EMBL European molecular biology laboratory
CTD Comparative toxicogenomics database
EGF Epidermal growth factor
FGF Fibroblast growth factor
HDAC Histone deacetylase
IGF-1 Insulin growth factor
TGF Tumor growth factor
AED 5-Androstenediol
G-CSF Granulocyte-colony stimulating factor




ACE Angiotensin converting enzyme 
ABTS 2,2’-azino-bis(3-ethylbenzothiazoline-6- 
  sulphonic acid)
        DPPH 2,2-diphenyl-1-picrylhydrazyl
        FRAP Fluorescence recovery after photobleaching
1. INtroductIoN
Recently, there has been spurt in research on radioprotective 
agents due to incidents like leakage of radioactivity in 
Fukushima, Japan1 and Mayapuri incident in Delhi2. Radiation 
causes ionisation of atoms in cells and tissues, resulting in 
damaging effects on the whole body. This leads to induction 
of mutations, chromosomal aberrations and cell death (or 
apoptosis). To decrease the radiation induced cellular injury, 
various drugs, chemical and biological compounds were tested, 
for example; thiol group (-SH) containing compounds (e.g., 
Aminofostine), Melatonin (N-acetyl-5-methoxytryptamine), 
NOS inhibitors etc3. Among these, sulfhydryl compounds 
have been the most extensively used. These agents are very 
good radioprotectors when given before X-ray exposure, but 
are very toxic in humans and do not provide any differential 
protection to normal tissues4. Studies have suggested that 
certain physiological substances such as cAMP5 and some 
vitamins (A, C and E) may be of radioprotective value for 
normal cells6-7. Calcium antagonists are also considered as good 
radioprotective agents with minimal toxicity8, nonetheless, the 
specificity of its effect for normal cells is unknown. Similarly, 
other compounds have been shown to have radioprotective 
ability in lab testing (Table 1)3. However, Amifostine is the 
only clinically used drug for decreasing radiation injury. It 
is used for a narrow medical indication i.e., for reduction of 
xerostomia (dry mouth) that results from salivary gland injury 
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abstract
Ionising radiation (IR) is responsible for various types of tissue injury leading to morbidity at low doses and 
mortality at high radiation exposure. Although many radioprotective and pharmacological agents are being tested for 
decreasing radiation injury, however, the availability of Amifostine as the only clinically used radioprotector with 
limited indication has prompted us to find out new potential molecules through drugs repurposing for protecting 
or decreasing radiation damage by data mining. In this work we have used text-mining based network generation 
approach to find out the gene targets of radioprotectors under evaluation by Agilent Literature Search app in Cytoscape. 
Extracted genes were evaluated for their association with radiation in Radiation Genes database. These genes were 
searched against therapeutic drugs and molecules under clinical trial in the Drug Gene Interaction database. We 
found that most of the radiation target genes were involved in cell death, proliferation, homeostasis, cell cycle and 
cancer pathways. Many of these genes were druggable and could be targeted by the drugs under clinical research, 
whereas there were few genes (new targets), which were never considered for radioprotective drug development. 
This study would likely help in repurposing of identified drugs for use in the event of radiation fallout, keeping in 
mind that no radiation medical countermeasure for acute radiation syndrome has been approved by the US FDA 
for use in humans. Results also revealed new target genes for drug targeting and indicates use of similar pipeline 
in other pathologies for drug repurposing and development. 
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Table 1. Classification of radioprotective agents and their mechanism of action. Agents evaluated in labs across the world for 
radioprotection, yet, none is used clinically for radiation protection except Amifostine
Group Radioprotective agents Mechanism of action
Thiols (-SH) Cysteines, mercaptoethylamine, cystamine, amino ethyliso-
thiourea dihydrobromide, 2-mercaptoethylguanidine 
Free radical scavenger; production of hypoxia; formation 
of mixed disulfide bonds; reversible DNA inhibition
Other Sulfur com-
pounds
Thiourea, thiouracil, dithiocarbamates, dithioxamide, thiazo-
lines, sulfoxides, sulfones, dimethylsulfoxide
Free radical scavenger; production of hypoxia; formation 
of mixed disulfide bonds; reversible DNA inhibition
Pharmacological 
agents
Ethyl alcohol, morphine, heroine, sodium salicylate, reserpine, 
acetylcholine, metacholine, carbaminoylcholine, epinephrine, 
methoxamine, dopamine, histamine, serotonin, estradiol, estro-
gen, colchicines, melatonin, melanocyte-stimulating hormone




Cyanide, 5-hydroxy-4-methyluracil, 5-amino-4-methyluracil, 
5-amino-4-mehtyl cytosine, AMP/ATP, pyridoxal-5-phosphate, 
sodium fluoroacetate, para-aminopropiophenone, melittin, ty-
phoid-paratyphoid vaccine, imidazole, cAMP
Miscellaneous
in patients undergoing radiotherapy for the treatment of head 
and neck cancer9. 
Drug repurposing/ drug re-profiling/ therapeutic switching 
is the application of known drugs and compounds to new 
diseases. An advantage of drug repositioning over routine drug 
development is that since the repositioned drug has already 
passed a number of pre-clinical and clinical phase, its safety is 
known and the risk of failure due to adverse effects are reduced. 
In addition, repurposed drugs can bypass much of the initial cost 
and time needed to bring a drug to market10. Repurposing of 
drugs utilises the relationship among genes, drugs, diseases and 
pathways, existing in databases. The relationship is displayed in 
the form of network for discovering potential drug targets. This 
strategy is likely to miss the information available in literature 
only and if no inter-relationship among molecules/ drugs has 
been established. Unavailability of this critical information 
in databases has detrimental effect on drug discovery and 
repurposing. Semantic-based biological networks generation 
integrates drugs, genes diseases, pathways and SNPs into one 
system for discovering potential drug targets. This technique 
extracts functional relationship between genes and generate 
network if two genes are frequently mentioned in the same 
sentence. Also, literature association networks are useful as a 
general search tool, since each link is referred to the supporting 
publication11. However, this may require some refinement by 
removing unrelated hits. 
Network based discovery can be used to identify on-target, 
off-target and indirect effects, thus helping in the identification 
of novel therapeutic opportunities for drug repositioning12. 
In this work, we have used literature mining and networking 
tools to identify gene targets of radioprotectors. The identified 
genes were screened against already available drugs/molecules 
for decreasing radiation injury. Agilent literature search 
(ALS)11, one of the Cytoscape13 app was used to find out the 
genes and their interaction on the basis of text-mining. The 
input terms were related to radiation and radioprotection in 
radiation genes database14 to find out their involvement in 
radiation induced pathways. The function of each gene in the 
interaction was found by using ClueGO app15. Further, the 
clinical/ experimental drugs/ molecules available against these 
genes were identified from DGIdb16. The drug-gene network 
was relayed in Cytoscape to display all the drugs/chemicals 
targeting identified genes. This network helped us in predicting 
the drugs, which are being used in some other pathology but 
could be tested as radiation medical counter measure (MCM) 
in humans exposed to undesired radiation.
2. materIals aNd methods
2.1 Agilent Literature Search for Candidate Genes
ALS is a meta-search tool for automatically querying 
multiple text-based search engines (both public and proprietary) 
to aid manual searching and extracting associations among 
genes/proteins of interest11. ALS was used in conjunction with 
Cytoscape, which generated a network view of gene/protein 
associations. The query terms related to radiation were entered; 
the retrieved results were fetched from their respective sources. 
Each resulting document was then parsed into sentences and 
analysed for protein-protein associations. ALS app used a set 
of ‘context’ files (lexicons) for defining protein names (and 
aliases) and association terms (verbs) of interest. Lexical parser 
was able to tell the subject and direct object from a sentence. 
Associations extracted from the documents were collected into 
a Cytoscape network. The sentences and source hyperlinks 
for each association were further stored as attributes of the 
corresponding Cytoscape edges. The coding genes for detected 
proteins were further searched in Radiation Genes database to 
find out their role with reference to radiation9. The Radiation 
Genes database collects microarrays data on transcriptional 
effects of ionising radiation obtained from public repositories 
or from published papers and supplementary materials. The 
database classifies it in terms of radiation quality, dose, dose 
rate and sample timing, so as to facilitate data integration and 
comparison.
2.2 ClueGO Functional Annotation
ClueGO app was used to visualise the non-redundant 
biological terms for large clusters of genes in a functionally 
grouped network constructed from ALS results. The radiation 
related genes symbols were uploaded in the ClueGO app. 
From the used ontology sources, the terms were selected by 
different filter criteria. The related terms which share similar 
and associated genes were used to reduce redundancy. The 
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ClueGO network was created with kappa statistics (this links 
the terms in the network) and reflected the relationships 
between the terms based on the similarity of their associated 
genes. Following parameters were selected for analysis; 
Analysis mode: Function; Ontologies/pathways: Biological 
pathways; Pathways selection with pV≤0.05; Enrichment/ 
depletion: By two sided hypogeometric test; pV correction: 
Bonferroni step down; GO term interval: 3-8; Pathways 
selection: number of genes/per cent genes; Selection of cluster 
consisting of: Minimum 3 genes and 8 per cent genes; Kappa 
score for pathway network connectivity: 0.4.
2.3 DGIdb Search for Genes to Drugs Mapping
To find out the drugs available for the genes targeted 
in radiation or radiation protection, the candidate gene list 
was analysed in DGIdb. It searched list of genes against 
a compendium of drug-gene interactions and potentially 
druggable genes. DGIdb organised genes of the druggable 
genome into two main classes. First, included genes with 
known drug interactions obtained by literature mining or by 
parsing publically available database. Second, included genes 
that may not currently be targeted therapeutically but are 
potentially druggable according to their membership in gene 
categories associated with druggability16. The gene list with 
associated drugs, interaction type and source of interaction was 
downloaded as .tsv file. 
2.4 Network Generation in Cytoscape
The network of genes with associated drugs and interaction 
type was generated in Cytoscape. The DGIdb .tsv file was used 
for this purpose. In order to visualise individual connected 
components, the network analyser was used for sub-network 
creation in ‘Tools’ menu of Cytoscape.
3. results
3.1 Agilent Literature Search
Two searches were performed, i.e. Search 1 and Search 2, 
with different search terms (Table 2). In Search 1, the search 
terms were categorised into 04 categories viz. radioprotective 
agent, pharmacological agents, mechanism of action and other. 
In Search 2, individual radioprotective agents, oncogenes, 
pharmacological agents and antioxidants were input as query 
terms.
The general term like ‘Facilitate DNA and cellular repair’ 
has been included in Search1 because irradiation (>1000 rads) 
of DNA solution in vitro has been shown to cause breakage 
of hydrogen bonds, chain breaks, cross-linkages, disruption 
of the sugar-phosphate backbone of DNA, impairment of the 
transforming ability of DNA, DNA base damage and inability 
of the DNA to act as a template for the synthesis of new DNA3. 
In mammalian cells, direct interaction of IR and DNA leads to 
single- and double strand breaks in DNA. Indirectly, IR induces 
formation of reactive oxygen species (ROS) through radiolysis 
of water, which causes DNA damage in cells. Therefore, a good 
radioprotector is attributed to have following characteristics; 
free radical scavenger, protect radio-oxidative damage, 
facilitates DNA and cellular repair, immune-modulatory and 
facilitates repopulation of damaged and affected organs22.
category Terms Reference
Radioprotective agents ExRad, hippophae rhamnoidea, Podophyllum hexandrum 17-19
Pharmacological agents Amifostine, Melatonin, 2-deoxyglucose 20, 21
Mechanism of action Free radical scavenging, radio-oxidative damage, facilitates DNA and cellular repair, 
immune-modulation, population of damaged and affected organs
3
Other Drugs for radiation injury, cell death and gamma radiation, radioprotectors, 
radiomitigators, ionising radiation
3
Radioprotective agents Sulphydryl compounds and irradiation 3
Radioprotective agents Cyclic nucleotides and irradiation 3
Radioprotective agents Eicosanoids and irradiation cytokines and irradiation 3
Oncogenes Oncogenes and irradiation 3
Pharmacological agent Pharmacological agents and irradiation 3
Radioprotective agents AS101 and irradiation 3
Radioprotective agents Calcium antagonists and irradiation 3
Antioxidants Antioxidant vitamins and irradiation 3
Antioxidants Vitamin and beta carotene and irradiation 3
Antioxidants Vitamin E and irradiation 3
Radioprotective agents Radioprotective agents 3
Table 2. Search terms queried in ALS to find out associated genes through text mining. The query terms in Search 1 and Search 2 
were input in als and option was set to use a homo sapiens concept lexicon to resolve aliases and to limit search engine 
‘hits’ to 5/search engine/query line. Entries in the query matched panel corresponded to the sentences found in the literature 
when that search was executed. An association was extracted for every sentence containing at least two concept names and 
one verb. Associations were then converted into interactions, which were further grouped into a network in Cytsoscape
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Figure 1. The orthogonal layout of Cytoscape network for Search 1 showing 14 individual components related to radiation terms. 
BCL-2 node had betweenness and closeness centrality37 in this network, indicating its importance. Directed arrows indicating 
flow of signal to and from a gene. pp: Extracted relationship on the basis of protein-protein interaction.   
Similarly in Search 2, ‘cAMP’ semantic was used, which 
is better known to have more general role in other cellular 
pathways. However the basic observation on radioprotective 
role of cAMP has been confirmed and extended by several 
investigators23-25. It was also suggested that a number of 
radioprotective agents, for e.g., sulfhydryl compounds, mediate 
their effect via cAMP26. The omission of this and similar terms, 
which have well established role in radiation protection, would 
have led to the missing of important leads in this study. 
Twenty references were found related to Search 1 and 38 
references were found corresponding to Search 2. On the basis 
of these references a network was generated in the Cytoscape 
(Figs. 1 and 2). The network consisted of genes (as nodes) and 
their interactions (as edges/ directed arrow). In case of Search 
1, fourteen independent networks were detected, among these 
the biggest network contained well known radiation associated 
genes such as p53, CDKN1A, ROS1, NOS2, ATM, and 
AKT13. Among the detected genes, except BCL-2, BCRA1, 
GLUTATHIONE, HOMOX1, PTPNSLC17A5, MPILC3B, 
H2AFX, NROB2, MIR25 and ALP1, other genes have been 
shown to be induced upon radiation exposure in microarray 
studies as detected in radiation genes database. However, 
exceptional genes are reported to be associated with radiation 
in scientific literature. 
For Search 2, BCL-2 was again found to have betweenness 
centrality for the biggest network among 09 independent 
networks. Among detected genes, the expression of BCL-2, 
PSML6, MCL-1, PTPN6, IF127 and VCP3 is not affected 
by radiation exposure as found out from Radiation Genes 
database results. 
3.2 Functional Annotation of Genes
In order to find the meaningful interpretation of the genes, 
their gene ontology was determined using ClueGO v2.1.6 
(Figs. 3(a), 3(b). GO describes gene products in terms of 
their associated biological processes, cellular components and 
molecular functions. Gene ID was used to input as identifier 
in ClueGO. A total number of 17 clusters were identified with 
18 GO term connections for Search 1. Most of the genes were 
found to be associated with apoptotic pathways, cell ageing 
and cell homeostasis. Detection of these genes indicates their 
involvement in radiation sensitivity or radiation protection. For 
Search 2, a total number of 86 clusters were identified with 
312 GO term connections. The target genes were detected for 
cell death, proliferation, homeostasis, cell cycle and cancer 
pathways. Detected genes were also involved in amytrophic 
lateral sclerosis and Chagas disease. These results indicate that 
most of the genes targeted for radiation damage and protection 
are involved in cell death pathway, suggesting importance of 
cell death related genes. In both searches, 08 common genes 
were detected viz. BCL-2, ATM, CDKN2A, FAS, NOS2, 
AKT1, PTPN6 and BAX. 
 
3.3 repurposed drugs
The genes identified in Search 1 and Search 2, were input 
in DGI database for their druggability. DGIdb integrates data 
from 13 primary sources covering disease relevant human 
genes, drugs, drug-gene interactions and potential druggability. 
The sources of drug includes Entrez genes27, Ensembl28, 
Pubchem29, dGene, Russ and Lampel druggable genes, Hopkins 
and Groom druggable genes, GO, My Cencer Genome, TALC 
(targeted agents in lung cancer), TEND (trends in exploration 
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Figure 2. 09 individual components were detected for Search 2, displayed in hierarchical layout in Cytoscape. Directed arrows 
indicating flow of signal to and from a gene. pp: Extracted relationship on the basis of protein-protein interaction.   
of novel drug targets), PharmGKB, TTD (therapeutic target 
database), DrugBank, CancerCommons, Clearityfoundation, 
STITCH, Supertarget, ChEMBL, Promiscuous and CTD. 
Search 1 resulted in 481 entries for drug interactions for 
the input genes (Figs. 4(a), (b)). It also found search terms 
matching one gene, but no interactions were present for 
them, which included MAPILC3B, ATG7, H2AFX, NROB2, 
KLRK1, CD226, CD244, BAX, SLC17A5, MIR25, BCL2L11, 
FOXO3, PRUNE2, RAD17, E2F4, MCPH1, USP8, ALPI, 
HIST2H2AA3, SUMO2, SUMO1, FAM20C, MT2A, PHIP, 
SI00A8, GABPA, PCNA, IFI27, SP7 and RUNX2. No matches 
were found for search terms BCRA1, Glutathione, HOMOX1, 
MPIL, C3B, SLC17A5 and NROB2. It was observed that 
SRC, Genes KCNH2, NOS1, PTEN, AKT-1, HTRC2, BCL-2 
and HMOX1 are most druggable genes whereas ≤5 drugs 
are available against AMBP, PPA1, APCS, ROS1, ATM, 
CDKN2A, JUN, FOS, FAS, CCHR1, DECR1, TP53, GPX4, 
GPX2 and SOD1. KCNH2, which is activated in response to 
drug and negatively regulate ion transport, was targeted by 
most of molecules in PharmGKB. In addition, highest number 
of drugs was found to target this gene.
Search 2 resulted in 326 entries for drug interactions 
for the input genes (Fig. 5(a), (b)). It also found search terms 
matching one gene, but no interactions were present for them, 
which included KITLG, SGCB, DIP, TET1, IF127, VCP3, 
ATP8A2, ATP8A2, BAX, BMX, PPP2R4. No match was 
found for search terms PSML6, IFI27 and VCP3. In Search 
2 also most of the genes were targeted by molecules in 
DrugBank as in Search 1. Maximum number of drugs in all the 
databases was found to target AKT1, which is a protein kinase 
B involved in myelin maintenance and spongiotrophoblast 
layer development. PPRA, CYP2BG, BCL-2, MAPK3/8, 
PAPR1, MIF and AKT1 were found to have more targeting 
drugs as compared to ACAT1, APART, FAS, PTPN6, MCL1, 
BCL2L1, CDKN1A, CDKN2A, PSMC6 and CREB1. 
In total, 32 genes were detected to be druggable in Search 
1 and 21 genes in Search 2 (Table 3). Druggable genes are 
those thought to be potentially druggable by various methods 
of prediction. These genes may/ may not have existing drugs 
that target them16. Of the two searches, 07 genes were found 
to be common, viz. BCL-2, ATM, CDKN2A, FAS, NOS2, 
AKT1 and PTPN6. If we look at the non-druggable genes, 
30 were from Search 1 and 10 were from Search 2. These are 
potential new target genes which were never explored for drug 
targeting. These genes are likely to have role in decreasing 
radiation induced cellular injury. BAX gene was found to be 
common between two searches, indicating its importance in 
radiation and radiation protection.
On the basis of drug-gene interaction. We have shortlisted 
few drugs which are likely to decrease injury upon radiation 
and may have repercussions in radiation MCM (Table 4). 
The drugs/ clinical trial drugs are available against genes viz. 
BCL-2, NOS2, PDK1 and KCNJ11 (for Search 1). These 
genes, except KCNJ11, are shown to modulate cell death. 
Similarly, drugs for genes ACAT1, BCL-2, PARP and NOS2 
(for Search 2) are available, which regulate cell survival16. We 
removed target genes (PDK1 and PARP1) corresponding to 
investigational/ clinical trial drugs for further analysis. 
Among the shortlisted drugs, the druggable genes 
common in both ‘Searches’, i.e. Bcl-2 and NOS2, are targeted 
by rasagiline and doxycycline, dexamethasone respectively. 
Rasagiline is an activator of anti-apoptotic protein Bcl-2, 
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Figure 3. GO terms specific for detected genes: Functionally grouped annotation network (organic layout) of the genes reflecting 
the relationship between the terms based on the similarity of the associated genes. The size of the nodes reflecting the 
enrichment significance of the terms. The degree of connectivity between terms (edges) was calculated using kappa statistics. 
Ungrouped terms are shown in white color. Group significance indicating the number of unique genes found from the 
uploaded genes as associated with the terms included in the group and the total number of unique genes associated with 
those terms. (a) Search 1. (b) Search 2.
(b)
(a)
which improves cell survival. It is more commonly known 
as monoamine oxidase inhibitor. Members of its class, 
clorgyline has been shown to protect nonmalignant human 
cells from IR and chemotherapy toxicity. The protective effect 
of clorgyline involves activation of anti-apoptotic pathways 
within the normal cell, which is supported by reduced level of 
apoptosis in HaCAT and in normal bladder explants cultures30. 
NOS2 (nitric oxide synthase) gene is expressed in liver and 
is inducible by a combination of polysaccharide and certain 
cytokines. Its transcriptional activation to produce nitric 
oxide is associated with cerebro-vascular endothelium cell 
death31. Inducible nitric oxide synthase has also been shown 
to regulate T cell death and immune memory32. Dexamethsone 
and doxycycline are inhibitor of this gene. Dexamethasone is 
349
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Figure 4. (a) Drug-gene interaction network for Search 1. Individual networks were extracted using Network Analyzer in Cytoscape. 
Networks are clustered arbitrarily from 1-6. Of the 65 search terms entered, only 54 were matched definitely, 01 has 
ambiguous matching and 01 did not have any match in the database. Number of interactions for definite matches were 
found to be 481. The central node in each network indicates radiation related gene. The peripheral nodes connected 
to central node are drug molecules extracted from DGIdb. Directed edges representing the mode of action of each 
drug on respective target gene. Few drugs, like Arsenic Trioxide, were observed to be commonly targeting multiple 
genes viz. KCNH2, JUN and AKT1. This drug likely to show side-effects/ off-target effects in vivo when used for 





Figure 5. (a) Drug-gene interaction network for Search 2. Individual networks were extracted using Network Analyser in Cytoscape. 
In total 31 search terms were entered, all terms matched definitely in the database. A total of 326 interactions showed 
definite matches.  Networks are clustered arbitrarily from 1-6. The nodes in cluster 3 and 6 represents gene and mode of 
action of drugs. Directed arrows representing targeting drugs/ database to genes viz. NOS2, AKT1, CYP2B6 and MIF. 
In cluster 5, although drugs were found to target PSMC6 and CDKN17 genes but their effect on respective gene is still 
unknown. In cluster 1, 2 and 4, central node represents gene, surrounded by targeting drugs (peripheral nodes). U/N: 
unknown interaction. (b). Number of drugs available for each gene in databases for Search 2.
(a)
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Genes for which drugs available (Druggable)
Search 1 Search 2 Common genes
PDK1, SULT1A1, CYP2E1, BIRC6, 
CCHCR1, KCNH2, KCNJ11, EPHX1, 
TP53, BCL-2, BCRA1, ATM, CDKN2A, 
DECR1, GLUTATHIONE, APCS, FAS, 
HOMOX1, SOD1, NOS2, HSPG2, HTR2C, 
JUN, AKT1, PTEN, SRC, ROS1, AMBP, 
FOS, DDR1, PPA1, PTPN6
PARP1, PPARA, APRT, BCL2L1, 
ATM, BCL-2, ACAT1, FAS, CDKN2A, 
MAPK3, MAPK8, NOS2, AKT1, 
CYP2B6, MIF, STAT3, CREB1, 
PSML6, CDKN1A, MCL-1, PTPN6
7 common elements in ‘SEARCH 1’ 
and ‘SEARCH 2’:
BCL-2, ATM, CDKN2A, FAS, 
NOS2, AKT1, PTPN6
Genes for which no drug available (New targets)
Search 1 Search 2 Common genes
SLC17A5, MPILC3B, ATG7, BAX, 
H2AFX, NROB2, CD244, KLRK1, 
CD226, MIR25, BCL2L11, FOXO3, 
PRUNE2, RAD17, E2F4, MCPH1, USP8, 
ALP1, HIST2H2AA3, SUMO2, SUMO1, 
FAM20C, MT2A,  PHIP, S100A8, GABPA 
PCNA, IFI27, SP7, RUNX2
KITLG, SGCB, DIP, TET1, IF127, 
VCP3, ATP8A2, BAX, BMX, PPP2R4
1 common element in ‘SEARCH 1’ 
and ‘SEARCH 2’:
BAX
Table 3. Druggable/ Non-druggable genes (new targets) in Search 1 and Search 2. Genes identified in ‘searches’, which are druggable 
and new targets. In druggable gene category, 07 genes were found to be common whereas 01 gene was common in new 
targets category.
used to treat inflammatory conditions including allergies, skin 
conditions, ulcerative colitis and breathing disorders. It has 
been shown to modify radiation response in vitro cultured 
cells. Treatment of V-79 cells with dexamethasone results in 
1.3 fold decrease in D0
33.
The doxycycline class member, tetracycline 
hydrochloride, effectively scavenges free radical in ABTS, 
DPPH and FRAP assays34. This demonstrated its ability to 
scavenge γ-radiation induced free radicals by formation of 
malondialdehyde. It confers dose modification facto (DMF) 
of 2 and 4 at 100 μM and 250 μM respectively, and offers 20 
per cent protection at a lethal radiation dose of 9 Gy. The role 
of other drugs, levosimendan and diazoxide (both targeting 
KCNJ11 gene) and sulfasalazine (targeting ACAT1 gene), 
has not been established in radioprotection. But, there is 
strong possibility of their involvement as supported by our 
prediction on rasagiline, doxycycline and dexamethasone, 
which has confirmatory role in published literature. 
However, it will be interesting to see whether shortlisted 
drugs against genes (which are differentially regulated in 
microarray studies upon IR exposure) would have positive or 
negative effect on radiation injury mitigation. Further research 
on these drugs with respect to cell survival improvement upon 
IR is likely to answer these questions. 
Search 1
Genes Drugs (Trade name: therapeutic dose range) Interaction Source Drug indication
KCNJ11 Levosimendan (Daxim: 0.01-10μM) Inducer Drug Bank Calcium sensitizer for congestive heart failure
KCNJ11 Diazoxide (Proteoglycem: 200 μM) Inducer Drug Bank Anti-hypoglycemic
Search 2
ACAT1 Sulfasalazine (Azulfidine: 25-100 μM) Inhibitor Drug Bank Rheumatoid arthritis, psoriatic arthritis, 
reactive arthritis and arthritis associated with 
bowel inflammation
Common in Search 1 and Search 2
BCL-2 Rasagiline (Azilect: 1-10 μM) Activator Drug Bank Anti-parkinsons; Type A monoamine oxidase, 
induces neuroprotective Bcl-2
NOS2 Doxycycline (Doryx: 1 μg/ml) / Miconazole 
(10-9 to 10-5 M)
Inhibitor Drug Bank Antibiotic/ Antimycotic
NOS2 Dexamethsone (Baycadrone: 10-1000 μM) Negative 
Modulator
Drug Bank Glucocorticoid agonist
Table 4. Gene-drug association on the basis of their interaction and sourced file. Candidate genes, playing role in radiation signaling, 
against which drugs are available. Search 1 shortlisted KJNJ11 gene and Search 2 indicated ACAT1 as a potential target 
of drug. Bcl-2 and NOS2 genes were found to be common in both the ‘Searchs’ against which drugs are available; these 
drugs could be considered for repurposing     
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4. dIscussIoN
Attempting to translate research from animals to humans 
is not as efficient as studying humans directly as 92 per cent 
of drugs that passed preclinical testing failed in clinical 
trials35. Presently there are various candidate molecules being 
evaluated for radiation counter measure for ARS in mouse 
model namely 17DMAC, ALXN4100TPO, anticeramide 
antibody, AVX-470M, captopril, CBLB612, CBLB613, 
Delta-tocotrienol, EGF, Ex-Rad, FGF-P, Gamma-tocotrienol, 
Genistein, GRI977143, HDAC inhibitors, IGF-1, Leridistim, 
LY294002, R-spondin 1, Somatostatin analog (SOM230), 
superoxide dismutase, Tempol, TGF-Beta and Tocopherol 
succinate. Others like 5-AED, AEDL, 10150, Amifostine, 
CBLB502, G-CSF, GM-CSF, IL12 and PEGylated G-CSF are 
being tested in non-humans primates for radiation syndrome 
as MCM. Chances of these candidate molecules clearing all 
phases of drug development are bleak as in the last 16 years 
only 05 molecules have been approved by US FDA to be used 
as drug under animal rule. Among these molecules ‘none’ has 
utility for ARS36.
Despite the fact that drug development remains a long and 
arduous journey, the prospect of genome based therapy remains 
an extremely exciting one. The possibility of treatment based 
on the genomic readout is now becoming a reality. In this study, 
by establishing relationship among heterogeneous dataset on 
parsing literature terms in ALS, biological network related to 
radiation is generated. This method is most appropriate when 
a subject related information is not integrated in databases and 
scarcity of this information is inconclusive for the investigation. 
In such a situation, text-mining based networks identify more 
general association types and offer an alternative network 
source when interaction data is limited.
On the basis of drug-gene interaction, we shortlisted few 
drugs against genes, which are likely to decrease cell death 
upon irradiation? The drugs/ clinically tried drugs are available 
against genes viz. PTPN6, PTEN, Bcl-2, NOS, PDK1 and 
KCNJ11 (in Search 1), which modulate cell death. Similarly, 
drugs for genes ACAT1, Bcl-2, PARP1 and NOS2 (in Search 
2) are available, which regulate cell survival. These drugs are 
potential molecules, likely to show good efficacy in MCM for 
radiation injury. These shortlisted drugs may be stockpiled, after 
thorough validation, to be used in case of medical emergency 
arising due to radiation injury, such as Chernobyl nuclear 
accident in which 29 people died among 203 hospitalised. 
The repurposing of these drugs for MCM could remove 
the initial 1-1.5 years of preclinical and Phase I development 
time in drug development. However, the later stages of the 
regulatory review process for these repositioned drugs would 
remain same as with new chemical entities – because research 
would be conducted on a different target population with a 
correspondingly different set of efficacy criteria.
5. CONCLUSIONS
Radioprotective drug development has suffered with 100 
per cent failure rate before reaching to culmination point. This 
subsumes dearth of radiation genes-drug association, which 
makes the task of drug repurposing very difficult. The text-
mining based identification of gene-drug association in this 
study would help in repurposing of under trial and clinical 
drugs to be tested in radiation exposed individuals. However, it 
should be confirmed that a valid association exists in between 
detected gene-drug pair with pre-clinical validation of results 
before delving into the clinical phase. The success of this 
strategy also depends upon the careful selection of search 
terms, the inclusion of general terms or unrelated terms likely to 
fetch unreliable results and makes the interpretation doubtful. 
Nevertheless, this strategy has potential to find out drugs and 
new targets for other pathologies, whose information is lacking 
in interaction databases and exists only in literature. 
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